2018 Pipeline Insight for Primary Biliary Cirrhosis - ResearchAndMarkets.com

DUBLIN--()--The "Primary Biliary Cirrhosis - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

This report outlays comprehensive insights of the present scenario and growth prospects across Primary Biliary Cirrhosis.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 20+ products along with 20+ companies involved.

Products Covered by Phase

  • Phase II and Phase I
  • Pre-clinical
  • Inactive (Dormant and Discontinued)

Scope of the Report

  • Provides an overview of therapeutic pipeline activity for Primary Biliary Cirrhosis across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Primary Biliary Cirrhosis therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Primary Biliary Cirrhosis

Companies Mentioned

  • Zydus Cadila
  • Tiziana Life Sciences
  • Pharmakea Therapeutics
  • Novartis
  • NGM Biopharmaceuticals
  • Kowa Pharmaceutical
  • Gilead Sciences
  • GenKyoTex
  • Genfit
  • Fast Forward Pharmaceuticals
  • Enanta Pharmaceuticals
  • Eisai
  • CymaBay Therapeutics
  • Arena Pharmaceuticals
  • Virobay
  • UCB Pharma
  • Shire
  • Regulus Therapeutics
  • NovImmune
  • GlaxoSmithKline
  • Falk Pharma GmbH
  • Biogen Idec/Genentech
  • Albireo Pharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/pmdwlk/2018_pipeline?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs